Market Overview

AbbVie Shares Double In A Year; Leerink Moves To Sidelines

Share:
AbbVie Shares Double In A Year; Leerink Moves To Sidelines
Related
Jim Cramer Weighs In On Arch Coal, AbbVie And More
Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial
Bbr Partners, Llc Buys Apple Inc, Exxon Mobil Corp, AbbVie Inc, Sells iShares MSCI EAFE, Cisco ... (GuruFocus)

AbbVie Inc (NYSE: ABBV) shares ran up about 14 percent last Friday following the release of fiscal fourth-quarter results, where it revealed expectations for higher earnings and a lower tax rate in 2018.

The Analyst

Leerink analyst Geoffrey Porges downgraded shares of AbbVie from Outperform to Market Perform, with the move attributed to the stock's run over the past six months.

The analyst upped the price target for the shares from $105 to $127 on the premise of a dramatically lower tax rate and strong performance of existing products as well as positive views on the company's pipeline.

The Thesis

All the positives are now more or less fully valued into AbbVie's stock, making it hard to justify the incremental upside needed to maintain an Outperform rating, Porges said in a Monday note.

Following the earnings announcement, the analyst increased his revenue forecast for AbbVie by 1-2 percent long-term.

Leerink estimates remain 4-5 percent higher than near-term consensus expectations, and the firm also hiked EPS estimates for the out years.

The new price target assumes predictable erosion of Humira in regions where it faces direct biosimilar competition, Porges said. 

"Naturally AbbVie's stock could offer more upside if all of its mid-to-late-stage pipeline succeeds, but we have significant revenue contributions in our model already for upadacitinib, risankizumab, Elagolix, and Rova-T," the analyst said. 

Leerink does expect some risk to its revenue forecasts for several of the figutres, given the competitive intensity in the sapce. 

Among large-cap pharma stocks, the firm said it now prefers Celgene Corporation (NASDAQ: CELG) to AbbVie. Additionally, Leerink said growth names such as Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) offer more upside than AbbVie.

The Price Action

Shares of AbbVie are up over 100 percent over the past year, including Friday's run-up.

At the time of writing, the shares were giving back 0.61 percent to $122.42.

Related Links:

Pharma M&A Picks Up Momentum

PFE, LLY, MRK Write Up 'Scripts For Q4

Latest Ratings for ABBV

DateFirmActionFromTo
Jul 2018Bank of AmericaMaintainsBuyBuy
Jul 2018BerenbergInitiates Coverage OnHold
Jun 2018ArgusMaintainsBuyBuy

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: Geoffrey Porges Humira LeerinkAnalyst Color Downgrades Price Target Analyst Ratings Best of Benzinga

 

Related Articles (ALXN + ABBV)

View Comments and Join the Discussion!

Vetr Crowd Downgrades ON Semiconductor

Pete Najarian Sees Unusual Options Activity In VanEck Vectors Oil Services ETF